A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Asses the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)

Trial Profile

A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Asses the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use
  • Sponsors ViroMed
  • Most Recent Events

    • 03 Aug 2017 According to a VM BioPharma media release, the first patient has been dosed in this trial.
    • 26 Jul 2017 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
    • 26 Jul 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top